According to the Center for Drug Evaluation (CDE) website, China-based Nuwacell Biotechnology Co., Ltd. has obtained approval for its NCR101 to conduct clinical trials in interstitial lung disease (ILD).
Drug Profile
NCR101 is an induced pluripotent stem cell (iPSC)-derived mesenchymal-like cells (MSCs) therapy. The product has achieved large-scale production and ensures high homogeneity of iMSCs between different batches, significantly enhancing consistency and reliability.-Fineline Info & Tech
